Sevil Ozcan

Title: Sevil Ozcan: Innovator in Proteasome Inhibition

Introduction

Sevil Ozcan is a notable inventor based in Lutz, FL (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of proteasome inhibitors. With a total of 2 patents, his work focuses on innovative approaches to cancer treatment.

Latest Patents

Ozcan's latest patents include groundbreaking research on proteasome chymotrypsin-like inhibition using PI-1833 analogs. This work involves focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor. The lead compound developed from this research strongly inhibits CT-L activity. Structure-activity relationship studies indicate that the amide moiety and two phenyl rings are sensitive to synthetic modifications. Notably, only para-substitution in the A-ring is crucial for maintaining potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and the meta-pyridyl group at the B-ring significantly enhance inhibition. The meta-pyridyl moiety also improves cell permeability. Furthermore, the length of the aliphatic chain at the para position of the A-ring is critical, with propyl yielding the most potent inhibitor. In contrast, shorter or longer chains demonstrate progressively less potency. The introduction of a stereogenic center next to the ether moiety shows chiral discrimination in proteasome CT-L activity inhibition, with the S-enantiomer being 35-40 times more potent than the R-enantiomer.

Career Highlights

Sevil Ozcan is affiliated with the H. Lee Moffitt Cancer Center and Research Institute, Inc. His work at this esteemed institution has allowed him to focus on innovative cancer therapies. His research has the potential to significantly impact the treatment of various cancers through the development of effective proteasome inhibitors.

Collaborations

Ozcan collaborates with talented individuals in his field, including Harshani Lawrence and Said M Sebti. These collaborations enhance the research efforts and contribute to the advancement of cancer treatment methodologies.

Conclusion

Sevil Ozcan is a prominent inventor whose work in proteasome inhibition is paving the way for new cancer therapies. His innovative research and collaborations are vital in the ongoing fight against cancer.